Gold rally may be losing steam but no major correction seen: DB
Investing.com - BTIG initiated coverage on Perspective Therapeutics Inc (NYSE:CATX) with a Buy rating and set a $14.00 price target on Friday. The stock, currently trading at $3.86, sits well below the broader analyst target range of $5.00 to $20.50, according to InvestingPro data.
The research firm identified Perspective as a leader in next-generation radiopharmaceuticals, highlighting its proprietary expertise in developing lead-212 isotope based therapies that potentially offer greater efficacy and improved safety compared to first-generation agents.
BTIG analyst Jeet Mukherjee noted the company’s current market capitalization of $289 million presents room for share appreciation ahead of key catalysts at ESMO and throughout 2026 across multiple programs.
The firm emphasized that despite increasing competition in the radiopharmaceutical space, Perspective’s investments in a U.S. regional manufacturing network create significant barriers to entry for competitors.
BTIG also pointed to the company’s technical expertise in lead-based radiopharmaceuticals as providing scarcity value that should maintain long-term interest from pharmaceutical strategic partners.
In other recent news, Perspective Therapeutics reported significant developments in its ongoing clinical trials and financial performance. The company announced its second-quarter 2025 results, highlighting progress in its VMT-a-NET Phase 1/2a trial for neuroendocrine tumors, with 39 additional patients treated at the 5 mCi dose level. Eleven of these patients have reached at least 32 weeks of follow-up, with further data expected at the upcoming European Society for Medical Oncology (ESMO) conference. Additionally, Perspective Therapeutics will present updated data on its [212Pb]VMT-α-NET program, showcasing safety and preliminary efficacy results from 44 patients.
Analyst firms have responded to these developments with varied ratings. H.C. Wainwright reiterated its Buy rating and maintained a $10.00 price target, citing the company’s ongoing clinical trials as a positive indicator. UBS also maintained a Buy rating with a higher price target of $18.00, reflecting optimism about the trial’s progress. In contrast, Oppenheimer lowered its price target from $15.00 to $14.00, while still maintaining an Outperform rating, following the company’s recent financial results and business updates. These updates are crucial for investors monitoring Perspective Therapeutics’ advancements in cancer therapy.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.